The INT-777 R-enantiomer is primarily studied for its potential therapeutic applications in metabolic and inflammatory diseases. It acts as a selective TGR5 receptor agonist, which plays a significant role in regulating glucose homeostasis and energy metabolism. Research suggests it may be beneficial in treating type 2 diabetes by enhancing insulin sensitivity and promoting glucose uptake in tissues. Additionally, its anti-inflammatory properties make it a candidate for addressing conditions like non-alcoholic steatohepatitis (NASH) and other liver-related disorders. The compound has also shown promise in modulating bile acid metabolism, which could aid in managing obesity and related metabolic syndromes. Ongoing studies are exploring its potential in neurodegenerative diseases due to its neuroprotective effects.